Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Long-Term Use of Insulin Glargine Maintains Glycemic Control: Presented at ADA

        By Jill Stein
        Special to DG News

        SAN FRANCISCO, CA -- June 17, 2002 -- Insulin glargine maintains its efficacy in glycemic control and its safety profile in the long-term management of patients with type 1 diabetes, with minimal effects on body weight, according to an international study.

        Dr. Manfred Dreyer, with Bethanien Hospital in Hamburg, Germany, reported the results here Saturday at the 62nd Scientific Sessions of the American Diabetes Association (ADA).

        His study, a 36-week extension of a 28-week multinational, multicenter randomized, open trial, examined the long-term efficacy and safety of insulin glargine when administered in combination with preprandial regular human insulin to patients with type 1 diabetes. Insulin glargine, marketed under the name Lantus by Aventis Pharmaceuticals, is a long-acting human insulin analog developed to have a smooth activity profile with no pronounced peaks and a duration of action suitable for once-daily administration.

        In Dr. Dreyer's extension study, 218 eligible patients from the original trial continued taking individually titrated subcutaneous insulin glargine at bedtime in combination with short-acting human insulin before meals. Patients' mean age was 39.5 and mean baseline hemoglobin A1c (HbA1c) level was 8.2 percent.

        Results showed that the level of glycemic control achieved in the preceding 28-week study was maintained in this 36-month extension study. A further decrease in HbA1c from baseline to end point of the extension study of 0.41 percent was noted.

        Long-term administration of insulin glargine did not reveal any unexpected adverse events compared with the previous study and other short-term studies. The incidence of severe hypoglycemia episodes was low.

        Insulin glargine had a minimal effect on body weight, with an average increase of 0.75 kg from baseline to end point.

        Insulin glargine was not associated with an adverse immunologic response.

        The results show that long-term insulin glargine therapy in patients with type 1 diabetes provides effective glycemic control and is well tolerated when administered once daily at bedtime in a combination regimen with preprandial regular human insulin, said Dr. Dreyer.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send